Akoya Biosciences Q3 EPS $(0.26) Beats $(0.37) Estimate, Sales $25.21M Beat $24.54M Estimate
Portfolio Pulse from totan@benzinga.com
Akoya Biosciences (NASDAQ:AKYA) reported Q3 earnings per share (EPS) of $(0.26), beating the analyst consensus estimate of $(0.37) by 29.73%. This is a 44.68% increase over losses from the same period last year. The company also reported quarterly sales of $25.21 million, beating the analyst consensus estimate of $24.54 million by 2.75%. This is a 33.75% increase over sales from the same period last year.
November 08, 2023 | 9:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akoya Biosciences reported better than expected Q3 earnings and sales, indicating a positive financial performance.
Akoya Biosciences reported Q3 earnings and sales that beat analyst estimates, indicating a strong financial performance. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100